News
EQS-News: Abivax announces the resumption of its liquidity contract
EQS-News: Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2023
Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Transgene Reports Business Update and Q3 2023 Financial Position
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update and its
ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant
EQS-News: Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
EQS-News: Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
EQS-News: Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
EQS-News: Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing
ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant
Poxel Announces its Participation at Upcoming Investor Conferences
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab)
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq
Poxel Announces its Participation at Upcoming Scientific Conference
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023
EQS-News: Abivax files registration statement for proposed initial public offering in the United States
EQS-News: Abivax announces the release of its 2023 half-year financial report
Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Abivax presents first-half 2023 financial results
Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for
Transgene Announces Upcoming Investor Meetings
Regulatory News:
TRANSGENE (Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that Management will participate in
Poxel to Report 2023 First Half-Year Results and host a video conference on September 26, 2023
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Poxel Reports Cash and Revenue for the Second Quarter and First Half 2023 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Abivax appoints Patrick Malloy as Senior Vice President Investor Relations